Search 

Healthcare Venture Capital Fund headquartered in Shangahi

Biotech

国家纳米科学院与广东

Investor

CareAcross is a cancer-focused digital health company. Our offerings include personalized digital therapeutics via engaging online platforms. Our business services include real-world evidence, patient engagement & monitoring programs, & clinical trial recruitment.

Our clients include, among others, most of the top biopharma companies in oncology, medical devices companies, diagnostics providers, etc.  Our business services are primarily based on our core assets: direct access to patients, and access to & ownership of patient data. While our focus has been in the cancer therapeutic area through our deep expertise and network, our technology is applicable to any long term or chronic condition, and enables patient engagement and improved outcomes.

Among the outcomes we can share are:

• reduced incidence of side-effects by 11%
• 5x reduction in risk of cancer malnutrition
• 65% increase in physical activity
• 68% improved patient engagement.

The approach is based on scientific evidence & guidelines: CareAcross experts process peer-reviewed journal articles on a daily basis (the company has already analysed several thousands of such articles). The applicable ones are “translated” to lay terms by experienced content writers, continuously updating the content library. The library consists of text, visuals & videos, and currently contains >500,000 words of original, patient-friendly content.
The material is selected based on each patient’s needs as entered in brief questionnaires (built entirely dynamically): advanced dynamic algorithms match each patient’s situation & needs with the right material from the content library. The level of personalisation is so deep that there are modules offering >20,000 different material combinations; the algorithms identify the most relevant for each individual patient.

Additionally, clinicians can monitor patients' progress remotely, and unobtrusively, with intuitive graphs and ongoing data collection.

The current focus areas include comorbidities, side-effects, nutrition, exercise, weight control, emotional wellbeing, and more. Furthermore, and in order to cultivate long-term engagement, CareAcross employs various methodologies including personalised newsletters, notifications, quantified-self techniques with intuitive scores & graphs, and others.
As a result, CareAcross delivers long-term, engaging, personalised coaching services to cancer patients, via material which is always available to them.
The approach does not aim to replace patients’ healthcare teams and clinicians, but to support patients in the majority of their time (95% on average) which they spend outside the clinic.

Our Patient Operations are active in several countries and continents.

Our Chief Medical Officer is a medical oncologist, and has been a president of the European Society for Medical Oncology (ESMO), among others. Our Chief Executive Officer is a member of the Assembly of the European Commission's Cancer Mission.

We have been awarded 3 grants by the European Commission on Big Data and Artificial Intelligence in Cancer enabling international collaborations with established centers of excellence.

We have been profitable in the last 4 accounting periods.

family office with investments in Europe, Asia and Latin America

Carmel Diagnostics is a medtech company who developed an innovative method for measuring Oxidative Stress (OS) of a biological liquid, a recognized biomarker of health and disease and a key diagnostics parameter. This OS parameter is measured by TCL (ThermoChemiLuminescence), an advanced yet simple technology. Carmel’s lead product is Embryo Selection in IVF process. Carmel won the prestigious Phase-2 grant from Horizon2020, planning market launch in H1/2021. It has an experienced, motivated team.

Leading business development strategy consulting firm, assisting clients in the pharmaceutical, biotech and healthcare investment industries for more than 25 years.
Three core lines of business, each focused on helping companies build and strengthen development.

Celumigen Pharmaceuticals is a California- headquartered seed stage specialty pharmaceutical company in dermatology focused on developing the first FDA-approved topical prescription immunotherapeutic drug for Cutaneous viral warts; a widespread global disease affecting greater than 500MM people in China, and 78% of the world's population. The global markets have seen no approved prescription therapies for HPV, Common warts and no therapies that eradicate this disease on the market or in the pipeline-- we plan to capture and grow this lucrative market. Our therapeutic is a likely 505 (b) 2 FDA designated drug. Our leadership, development and clinical team is a group of world class leaders with deep industry knowledge and unparalleled domain expertise. We have raised a seed round led by industry- leading investors which funded a Proof of Concept study with very positive confirmatory results and data to support our Phases I and Phase II. We are now seeking strategic partnership with a company seeking to support drug development to enhance existing dermatology drug asset portfolios or fund our program through venture capital / partnership.

Charnwood Molecular is an award-winning, UK-based CRO, which has been providing expert synthetic chemistry support for over 20 years. At Charnwood Molecular, we work with clients of all shapes, sizes and global standing. These range across a variety of sectors, from virtual start-ups to established global agrochemical, materials chemistry, diagnostics, biotechnology and pharmaceutical companies. All of our clients benefit from our proactive and open approach, geared towards rapidly advancing projects towards important key decision points and beyond.